NewTrimEra Reta-Tri
Triple-agonist investigational therapy. The frontier of incretin science.
Investigational triple agonist of GIP, GLP-1, and glucagon receptors under late-stage clinical evaluation, with the largest weight-loss magnitudes reported in any phase-2 obesity trial to date.
How it works
Adds glucagon receptor agonism to dual incretin activity, increasing basal energy expenditure while preserving the appetite-suppressing benefits of GLP-1 / GIP co-agonism.
What the evidence shows
Phase-2 trial: −24.2% mean body weight at 48 weeks (12 mg cohort).
Significant reductions in hepatic fat content (>80% in MASLD subgroups).
Currently in phase-3 TRIUMPH program.
Not yet FDA-approved — research and educational reference only.
Cited data reflects published clinical trials of the underlying molecule. Individual response varies. Statements have not been evaluated by the FDA.